ArticleLiver cancer2021

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.

Shukui Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.